Skip to main content
letter
. 2022 Nov 24;179:121–123. doi: 10.1016/j.ejca.2022.11.016

Fig. 1.

Fig. 1

SARS-CoV-2 anti-S1 IgG antibody titres before and after a fourth dose BNT162b2 in cancer patients. SARS-CoV-2 anti-S1 IgG antibody titres 28 days and 6 months after third BNT162b2 dose and 28 days after fourth BNT162b2 COVID-19 vaccine in the different treatment cohorts. Subjects were assigned to treatment cohorts based on the therapy received at time of the third dose. The height of each bar represents the geometric mean titre (GMT) ± standard error of the mean. Anti-S1 IgG-class antibody titres were quantified using a SARS-CoV-2 Immunoassay, Siemens Healthineers Atellica IM SARS-CoV-2 IgG (sCOVG) assay for the detection of antibodies (BAU/mL). Measuring interval: 10.90–16350.00 BAU/mL. Values below the detection were imputed half of it (5.45 BAU/mL), values above the measuring interval were imputed 33% above the upper limit of detection (21,800 BAU/mL) with dotted line indicating LLQ and ULQ, respectively.